These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 39035009)

  • 1. First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis.
    Yi L; Zhou Z; Zeng X; Tan C; Liu Q
    Front Immunol; 2024; 15():1408928. PubMed ID: 39035009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China.
    Kang S; Liu H
    Expert Rev Pharmacoecon Outcomes Res; 2024 Nov; 24(9):1081-1088. PubMed ID: 37936507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial.
    Xiang H; Meng K; Wu M; Tan C
    Expert Rev Pharmacoecon Outcomes Res; 2024 Oct; 24(8):1043-1051. PubMed ID: 38984534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer.
    Liang X; Chen X; Li H; Li Y
    Front Public Health; 2023; 11():1156427. PubMed ID: 37727602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis.
    Zhu Y; Liu K; Qin Q; Zhu H
    Front Immunol; 2022; 13():1044678. PubMed ID: 36685541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective.
    Tong YH; Ding HY; Xin WX; Zhong LK; Xu GQ; Zhang B; Yang GN; Fang L
    Tumori; 2022 Feb; 108(1):33-39. PubMed ID: 33511911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China.
    Xiang G; Jiang T; Gan L; Wu Y; Zhang N; Xing H; Su H; Li Y; Peng D; Ni R; Liu Y
    Front Immunol; 2023; 14():1223020. PubMed ID: 37720211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing.
    Shao T; Zhao M; Liang L; Tang W
    BioDrugs; 2023 May; 37(3):421-432. PubMed ID: 36840914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China.
    Liu S; Jiang N; Dou L; Li S
    Front Immunol; 2023; 14():1172242. PubMed ID: 37215110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis.
    Wang S; Li Y; Liu Z; Tian W; Zeng Y; Liu J; Zhang S; Peng Y; Wu F
    Lung Cancer; 2023 Apr; 178():47-56. PubMed ID: 36774774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review.
    Wang T; Li Y; Zheng X
    BMC Health Serv Res; 2023 Jun; 23(1):691. PubMed ID: 37365540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
    Liu Q; Tan C; Yi L; Wan X; Peng L; Li J; Luo X; Zeng X
    PLoS One; 2021; 16(11):e0258605. PubMed ID: 34780478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line serplulimab plus chemotherapy versus chemotherapy in PD-L1-positive esophageal squamous-cell carcinoma: a cost-effectiveness analysis.
    Liang X; Meng M; Qin S; Chen X; Li Y
    Sci Rep; 2024 Jun; 14(1):14496. PubMed ID: 38914660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis.
    Peng J; Xu H; Liu Q
    PLoS One; 2024; 19(10):e0312133. PubMed ID: 39423210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis.
    Du J; Wang X; Fan L; Shan X; Li M; Liu L
    Heliyon; 2023 Apr; 9(4):e14794. PubMed ID: 37095958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
    Zhou K; Zhou J; Huang J; Zhang N; Bai L; Yang Y; Li Q
    Lung Cancer; 2019 Apr; 130():1-4. PubMed ID: 30885327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis.
    Kang S; Wang X; Zhang Y; Zhang B; Shang F; Guo W
    Front Oncol; 2021; 11():740091. PubMed ID: 35127468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
    Wen F; Huang P; Wu Q; Yang Y; Zhou K; Zhang M; Li Q
    Cancer Med; 2024 Aug; 13(16):e70094. PubMed ID: 39149756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China.
    Li LY; Wang H; Chen X; Li WQ; Cui JW
    Chin Med J (Engl); 2019 Dec; 132(23):2790-2794. PubMed ID: 31856049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients.
    Zheng H; Zeng Y; Wen F; Hu M
    Front Immunol; 2024; 15():1382088. PubMed ID: 38711525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.